NasdaqCM:IMUXBiotechs
Immunic (IMUX) Is Up 27.8% After Securing Oversubscribed $400M Raise For MS Push – What's Changed
Immunic, Inc. recently secured an oversubscribed private placement of up to US$400.01 million and outlined plans to complete phase 3 trials and pursue regulatory approval for its multiple sclerosis candidate vidofludimus calcium, while also initiating a CEO search and refreshing its board to support an eventual commercial launch.
A distinctive aspect of this update is Immunic’s simultaneous push into both relapsing and primary progressive multiple sclerosis, coupled with bringing in...